Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 33c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $243.47 +2.51%
Revenue Growth %: +6.2%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
CRMT, More
Revenue Growth %: +6.2%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $3.22, $0.33 better than the analyst estimate of $2.89. Revenue for the quarter came in at $412 million versus the consensus estimate of $421 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2017 EPS of $10.70-$11.20, versus the consensus of $10.90. Jazz Pharmaceuticals sees FY2017 revenue of $1.6-1.65 million, versus the consensus of $1.64 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Bending Spoons closes IPO, raises ~$954M on Nasdaq
- RBC Capital Downgrades Bucher Industries AG (BUCN:SW) (BCHHF) to Sector Perform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
